Waltham, Mass.-based NeuroMetrix, Inc., a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, has announced the launch of a consumer website, www.SENSUSRx.com.
The website provides patients and physicians with a one-stop location for information about chronic pain such as painful diabetic neuropathy and the SENSUSTM Pain Management System.
The system is a wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The lightweight device can be worn during the day when users are active, or at night while they are sleeping. It is specifically designed for people with diabetes who suffer from chronic pain from diabetic neuropathy, which affects up to 5 million people in the United States alone.
The website contains a variety of content including interactive tools to help people evaluate and discuss chronic pain with their physicians, video testimonials of SENSUS users, and product support materials such as an instructional video. The website also contains social media features including a blog that will point visitors to the latest relevant research and provide updates on SENSUS and related technologies.
“PDN is a large problem in the diabetes community,” said Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix. “We believe that there is an important role for us to play in managing pain due to PDN, and that this website will be a useful tool to reach this audience. It contains a wide range of product and disease information that we intend to further expand over time.”
NeuroMetrix’s development and marketing focus is on home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The company is currently focused on diabetic neuropathies, which affect over 50percent of people with diabetes.
Besides SENSUS, the company also markets the DPNCheck® device, a point-of-care test for the detection of early-stage diabetic neuropathy.